Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-12-29 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
公司章程
Governance Information Classification · 100% confidence The document is titled '昆药集团股份有限公司章程' which translates to 'Articles of Association of KPC Pharmaceuticals, Inc.' It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, share repurchase, and other corporate governance matters. It includes sections on the general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution and audit, external investment and management, labor and personnel system, stakeholders, environmental protection and social responsibility, liabilities, notices and announcements, mergers, splits, capital increase and decrease, dissolution and liquidation, and amendments to the articles. The document is a comprehensive governance document that sets out the internal rules and structure of the company. It is not a financial report, earnings release, or announcement of voting results. It is not a proxy statement or remuneration report. It is a governance document detailing the company's internal rules and board structure. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance document, not just an announcement or summary.
2020-12-29 Chinese
关于公司参与投资基金暨关联交易事项的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding its participation in an investment fund and related party transactions. It includes extensive information about the investment fund, the related parties involved, the financial status of these parties, the terms of the investment, risk disclosures, and the approval process by the board and supervisory committee. The document is an official announcement about a specific transaction involving capital investment and related party dealings. It does not contain financial statements or comprehensive financial performance data typical of annual or interim reports. It is not a call transcript, earnings release, or audit report. The content focuses on a capital investment and related party transaction update, which fits the category of Capital/Financing Update (CAP). The document length (7995 characters) and detailed transaction description support this classification rather than a brief announcement or a regulatory filing fallback.
2020-12-29 Chinese
独立董事关于公司九届三十五次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting agenda items, including investment fund participation and guarantee provision. It references compliance with company law, securities law, and company articles, and discusses board procedures and related party transactions. The content is focused on board/management matters and governance compliance rather than financial results, audit, or regulatory filings. The document length is short (773 characters), and it is not a report or announcement of a report but an opinion related to board decisions. Therefore, it fits best under Board/Management Information (MANG).
2020-12-29 Chinese
九届三十五次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on various board matters such as amendments to the company charter, resignation of a vice president, investment fund participation, guarantees, and external investments. The content focuses on board decisions and management changes rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor an earnings release or regulatory filing. The document fits the category of Board/Management Information (MANG) as it announces changes and decisions made by the company's board of directors.
2020-12-29 Chinese
关于公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the national drug regulatory authority. It details the drug's registration information, market background, and potential impact on the company. There is no financial data, no mention of financial results, no meeting materials, no voting results, no management changes, no legal proceedings, no capital changes, and no earnings information. The document is a regulatory announcement about a product approval, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about a non-financial matter. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-12-21 Chinese
北京德恒（昆明）律师事务所关于昆药集团2017年限制性股票激励计划首次授予部分第三期限售解除的法律意见
Director's Dealing Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the third phase of lifting restrictions on a 2017 restricted stock incentive plan for Kunming Pharmaceutical Group Co., Ltd. It details the approval, authorization, and conditions met for the stock unlocking, including references to board meetings, shareholder meetings, and compliance with relevant laws and regulations. The document is a standalone legal opinion related to stock incentive plan matters, specifically about the lifting of restrictions on shares granted under the plan. It is not a financial report, earnings release, or general regulatory filing. It is also not a proxy solicitation or voting results announcement. The document focuses on legal opinions about stock incentive plan share unlocking, which aligns with Director's Dealing (DIRS) filings that report on share transactions or changes related to company directors and executives, especially in the context of stock incentives and restricted shares. Therefore, the most appropriate classification is Director's Dealing (DIRS). The document length (9651 characters) and content confirm it is a full legal opinion, not just an announcement or certification, so it is not RNS or RPA.
2020-12-16 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.